Germany strikes outcomes-based deal with Novartis for Kymriah

CAR T therapy Kymriah tisagenlecleucel will be available in Germany under an outcomes-based payment model, the country's first such agreement for a gene or CAR T cell therapy.

Novartis AG (NYSE:NVS; SIX:NOVN) and German health insurer GWQ ServicePlus AG agreed last week that the pharma will return an undisclosed portion of the therapy's cost to the insurer if a patient dies due to their cancer within an undisclosed period of time after treatment...